Payment overview · 2025
General Payments
$200.38
2 reported records · 2 companies
Healthcare provider profile · identity verified
James Edward Devlin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROCKWAY, PA · NPI 1306954722
Verified facts
What the public records show
CMS Open Payments records show James Edward Devlin, M.D. received $200.38 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 87.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.00 | 87.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.38 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $175.00 | 1 |
| Food and Beverage | $25.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1016 | 196 |
| Lisinopril | Lisinopril | 782 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 748 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 595 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 522 | 107 |
| Omeprazole | Omeprazole | 443 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 433 | 80 |
| Furosemide | Furosemide | 395 | 69 |
| Potassium Chloride | Potassium Chloride | 392 | 65 |
| Gabapentin | Gabapentin | 386 | 69 |
| Losartan Potassium | Losartan Potassium | 382 | 72 |
| Metformin Hcl | Metformin Hcl | 369 | 69 |
| Carvedilol | Carvedilol | 340 | 69 |
| Simvastatin | Simvastatin | 328 | 76 |
| Eliquis | Apixaban | 326 | 45 |
| Atenolol | Atenolol | 308 | 61 |
| Trazodone Hcl | Trazodone Hcl | 288 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 42 |
| Prednisone | Prednisone | 228 | 134 |
| Montelukast Sodium | Montelukast Sodium | 222 | 43 |
| Xarelto | Rivaroxaban | 222 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 210 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 195 | 26 |
| Finasteride | Finasteride | 195 | 32 |
| Sertraline Hcl | Sertraline Hcl | 195 | 39 |
| Allopurinol | Allopurinol | 194 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 48 |
| Mirtazapine | Mirtazapine | 172 | 27 |
| Ozempic | Semaglutide | 172 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 161 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 29 |
| Tramadol Hcl | Tramadol Hcl | 154 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 143 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 47 |
| Alprazolam | Alprazolam | 127 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 30 |
| Famotidine | Famotidine | 117 | 24 |
| Alendronate Sodium | Alendronate Sodium | 115 | 24 |
| Metformin Hcl Er | Metformin Hcl | 114 | 24 |
| Levetiracetam | Levetiracetam | 113 | 12 |
| Azithromycin | Azithromycin | 111 | 99 |
| Baclofen | Baclofen | 110 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 32 |
| Donepezil Hcl | Donepezil Hcl | 105 | 20 |
| Fentanyl | Fentanyl | 105 | 14 |
| Warfarin Sodium | Warfarin Sodium | 102 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 16 |
| Spironolactone | Spironolactone | 97 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 16 |
| Ezetimibe | Ezetimibe | 88 | 20 |
| Meloxicam | Meloxicam | 87 | 27 |
| Jardiance | Empagliflozin | 83 | 14 |
| Trulicity | Dulaglutide | 82 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 14 |
| Entresto | Sacubitril/Valsartan | 75 | 12 |
| Memantine Hcl | Memantine Hcl | 75 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 50 |
| Ramipril | Ramipril | 72 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 60 |
| Bumetanide | Bumetanide | 71 | 15 |
| Risperidone | Risperidone | 70 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 12 |
| Lorazepam | Lorazepam | 68 | 21 |
| Pregabalin | Pregabalin | 68 | 15 |
| Clonidine Hcl | Clonidine Hcl | 67 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 67 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | suppressed |
| Clonazepam | Clonazepam | 66 | 14 |
| Glimepiride | Glimepiride | 66 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 20 |
| Cephalexin | Cephalexin | 65 | 49 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | suppressed |
| Celecoxib | Celecoxib | 60 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | suppressed |
| Olanzapine | Olanzapine | 55 | suppressed |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Amoxicillin | Amoxicillin | 53 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 11 |
| Valsartan | Valsartan | 51 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Torsemide | Torsemide | 50 | 11 |
| Buspirone Hcl | Buspirone Hcl | 49 | 12 |
| Nystatin | Nystatin | 49 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Glipizide Er | Glipizide | 42 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Topiramate Er | Topiramate | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 18 |
| Meropenem | Meropenem | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Acebutolol Hcl | Acebutolol Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Mupirocin | Mupirocin | 22 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Neupro | Rotigotine | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 19 | 17 |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Symproic | Naldemedine Tosylate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.38 · 2 records | Amgen Inc. | PROLIA, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error